Nektar Therapeutics (NKTR) Return on Sales (2016 - 2025)
Historic Return on Sales for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to 2.97%.
- Nektar Therapeutics' Return on Sales fell 14300.0% to 2.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.81%, marking a year-over-year change of 0.0%. This contributed to the annual value of 1.21% for FY2024, which is 18500.0% up from last year.
- Latest data reveals that Nektar Therapeutics reported Return on Sales of 2.97% as of Q3 2025, which was down 14300.0% from 3.51% recorded in Q2 2025.
- In the past 5 years, Nektar Therapeutics' Return on Sales ranged from a high of 0.25% in Q4 2024 and a low of 7.37% during Q2 2022
- Over the past 5 years, Nektar Therapeutics' median Return on Sales value was 3.02% (recorded in 2022), while the average stood at 3.47%.
- Per our database at Business Quant, Nektar Therapeutics' Return on Sales crashed by -29400bps in 2022 and then soared by 48800bps in 2023.
- Nektar Therapeutics' Return on Sales (Quarter) stood at 5.87% in 2021, then surged by 49bps to 3.02% in 2022, then surged by 42bps to 1.76% in 2023, then skyrocketed by 114bps to 0.25% in 2024, then plummeted by -1297bps to 2.97% in 2025.
- Its Return on Sales stands at 2.97% for Q3 2025, versus 3.51% for Q2 2025 and 4.44% for Q1 2025.